Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GSK plc. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2]

Our board of directors is responsible for corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance. Our Chief …

Emma joined the Board as CEO Designate on 1 January 2017 and became CEO on 1 April 2017. She has been a member of the GSK Leadership Team since 2011, as the President and then …

Walmsley became CEO of GlaxoSmithKline in April of 2017, making her the first woman to run a major pharmaceutical company. In 2023, the U.S. FDA approved Arexvy, GSK's RSV vaccine, …

2 days ago · Emma Walmsley on navigating global politics and why inclusion still matters

GSK CEO Emma Walmsley’s $13 million salary is predicated on picking the right people to steer cutting-edge drug development for the world’s most challenging diseases. During her eight …

May 21, 2024 · When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 …

CEO’s statement “Our ambition is to drive a high-performance culture, putting science at the heart of GSK, remaining true to our values and our purpose: to help people do more, feel better, live …

May 31, 2023 · On this week’s episode of Fortune‘s Leadership Next podcast, co-hosts Alan Murray and Michal Lev-Ram talk with GSK CEO Emma Walmsley about the future of A.I. in …

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s...